Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs.
about
Self-limiting Atypical Antipsychotics-induced Edema: Clinical Cases and Systematic ReviewOn the Slow Diffusion of Point-of-Care Systems in Therapeutic Drug MonitoringPharmacointeraction network models predict unknown drug-drug interactionsPredicting in vivo drug interactions from in vitro drug discovery data.Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry.Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data.Role of valproate across the ages. Treatment of epilepsy in the elderly.Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sexChildren on phenobarbital monotherapy requires more sedatives during MRI.Safety and tolerability of antiepileptic drug treatment in children with epilepsy.Antiepileptic drug interactions - principles and clinical implications.Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies.The application of capillary electrophoresis techniques in toxicological analysis.Clinically relevant drug interactions with antiepileptic drugsAn evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS.Prioritizing children's medicines for research: a pharmaco-epidemiological study of antiepileptic drugsThe antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liverBrain tumor-related epilepsy.Zonisamide: newer antiepileptic agent with multiple mechanisms of action.Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study.A review of the effect of anticonvulsant medications on bone mineral density and fracture risk.Antiepileptic drug treatment in children.Pharmacokinetics and drug interactions with zonisamide.Seizure treatment in transplant patients.Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety.Medical Comorbidity and Complications.Safe Treatment of Seizures in the Setting of HIV/AIDS.Value of therapeutic drug monitoring in epilepsy.Therapeutic drug monitoring of phenytoin in critically ill patients.Effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on the protective action of various antiepileptic drugs in the maximal electroshock-induced seizure model: a type II isobolographic analysis.Drug interactions involving the new second- and third-generation antiepileptic drugs.Adjunctive antiepileptic drugs in adult epilepsy: how the first add-on could be the last.Generic substitution of antiepileptic drugs.Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases.Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.Patients with brain tumor-related epilepsy.Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.Methodologies used to identify and characterize interactions among antiepileptic drugs.Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: A retrospective observational cohort study using US administrative insurance claims.
P2860
Q26747614-44010E61-4DEB-47FF-9430-CAD43F4A6049Q27024074-55E32855-F98A-46F7-9C76-2DAAF4B2BFD0Q28486311-9CBAEA32-7C0A-4A20-BD83-077330B6D310Q31011412-17052F6A-78BC-48E3-856B-8698AF28C0F7Q31046235-69A1B0E4-7847-4966-897D-BA137596E207Q31110554-892DA200-31E8-40C2-980D-B703D9A497AEQ33153941-05CB562B-3A58-47C7-9C7C-FAAAE130AFA4Q33683890-F995BC3F-7E34-49B7-9251-5830D299F662Q34184523-970198E7-5A9E-49C0-862C-EAAE8DB05B0FQ34281872-8ECF396E-079B-4A52-B98B-D1A4A762661FQ34402188-9A6D248A-00C9-45C4-A95C-70E68539F451Q34469479-E64C71F0-37B2-487A-B785-AE00164EF311Q35168632-E971F8DC-38AA-4717-9DA5-B756256E24EFQ35827491-99F1506C-779A-4322-A45F-7FC5977CBC89Q35967040-39EFE95C-CB2B-4667-AF1A-4106E380C707Q36024450-3F5A1EFD-8106-4133-B351-A93DCB4114D6Q36053511-2172BAAA-1C55-4CA6-B0CF-32F942CC0D62Q36067319-9004CD22-C118-4227-86BB-C83CEB58F54BQ36106890-AE003536-ECBE-4733-8AC5-FECCC4E76954Q36110554-0C8247D0-2EB5-4765-A095-2445A9206CCFQ36605584-6B7EEFC2-FE18-4564-A56F-06F10045D766Q36730668-E89F258A-9BE8-40CA-90FB-5589532F51EDQ36744156-F04828E0-8251-4147-98E7-20AFA60C8FDDQ36851252-8ECC0631-30E3-4B8E-9984-EDAE04F2A709Q36960535-3AB5B7C1-97EB-4BC2-B891-340C3ABBBC75Q37037876-ACD44E01-9DFF-4AD6-AB4E-BE7FB365E7ACQ37096562-419B7211-DB3B-4928-8A44-A76178DCEBE4Q37174056-2AE6D278-D6A3-4193-979E-74D9304CC224Q37310486-B5936178-B5D9-4D08-A680-1A74BFE51BB1Q37325722-B5F80B95-D7CF-4B33-B8A0-47786FB0E6B9Q37658910-D86C7912-2D31-4FD2-BB78-620F1C0A51CCQ37733552-67118B73-97B0-4518-893F-7E6491FB2DEAQ37810997-BF0D4348-2041-4D1A-A4A9-7A770F704B22Q37875183-5150CA41-76E7-41F2-B7AF-0BC3BDDEEE05Q37992162-D8FB3948-4B63-46B3-B8B1-BAE363DC3355Q38005050-4A25A521-ECBB-4BCB-861A-931A440DEFA2Q38016227-84A70831-29D7-428F-9552-82996DF7CBB9Q38018676-AA558B6C-B0B5-4F28-80FB-CA7025DC3764Q38115721-A6BE46F9-9C65-46A0-8522-72CA3EAA03B1Q38236299-4AD7CAFC-AA7C-4691-B38F-5D023CFC08A6
P2860
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Clinically important drug inte ...... s between antiepileptic drugs.
@ast
Clinically important drug inte ...... s between antiepileptic drugs.
@en
type
label
Clinically important drug inte ...... s between antiepileptic drugs.
@ast
Clinically important drug inte ...... s between antiepileptic drugs.
@en
prefLabel
Clinically important drug inte ...... s between antiepileptic drugs.
@ast
Clinically important drug inte ...... s between antiepileptic drugs.
@en
P1433
P1476
Clinically important drug inte ...... s between antiepileptic drugs.
@en
P2093
Philip N Patsalos
P304
P356
10.1016/S1474-4422(03)00409-5
P577
2003-06-01T00:00:00Z